KROS at a glance
Keros Therapeutics, Inc. (KROS, SEC CIK 1664710) filed its latest 10-K annual report on March 4, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 16, 2026 and Form 4 insider filings as recently as November 19, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Keros Therapeutics, Inc. (KROS) reported revenue of $244.1 million (up 6775.0% from FY2024) and net income of $87.0 million. Diluted EPS was $2.30.
- As of September 30, 2026, 24 institutional investment managers tracked by SignalX reported holding Keros Therapeutics, Inc. (KROS) shares worth $103.7 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Newton Charles W. on November 17, 2026 of 491 shares at $10.83 per share.
- In the last 90 days, KROS insiders reported 0 open-market purchases ($0) and 5 open-market sales ($18K) on Form 4, a net sale of $18K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $244.1M
- +6775.0% vs prior year
- Insiders · 90 days
- 0 buys · 5 sells
- Net −$18K
- 13F holders
- 24 funds
- $103.7M · −2 vs prior quarter
- Latest 8-K
- Nov 16, 2026
- Item 8.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- Regulatory risk: EU Pharma Package could reduce orphan exclusivity from 10 to 9 years, accelerating generic or biosimilar competition
- Financial risk: $259.5 million cash and cash equivalents expected to fund operations into the second half of 2028
- Clinical risk: Cibotercept TROPOS trial terminated after unanticipated pericardial effusion adverse events
- Competitive risk: DMD competition expanded following Sarepta, Avidity Biosciences and Edgewise Therapeutics developments
- Compliance risk: UK clinical-trial amendments effective April 28, 2026 may increase CRO compliance costs and delay trial initiation
Management Discussion & Analysis
- Quarterly revenue $40.0M, up $25.7M YoY from $14.3M, driven by Takeda milestones
- Net income $14.2M vs $7.3M loss YoY, operating margin 32.0% vs negative 107.9%
- Rinvatercept R&D $5.0M, up $3.7M YoY, best-performing pipeline line
- Cash $259.5M; operating cash flow $(20.6)M vs $134.8M YoY
- Cash runway into second half of 2028; inflation, tariffs and capital-market volatility headwinds
AI summary of the KROS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- $5 million common-stock repurchase program approved after receiving a $20 million Takeda development milestone
- Cash and equivalents totaled $259.5 million as of September 30, 2026
Item EX-99.1: Item EX-99.1
- $5 million share repurchase authorization following $20 million elritercept development milestone payment from Takeda
- Capital return signals management views repurchases as an attractive use of milestone proceeds
Item 7.01: Regulation FD Disclosure
- Updated corporate presentation signals refreshed investor messaging and potentially new company or pipeline information
- Exhibit 99.1 contains the substantive presentation, available through Keros Therapeutics’ website
Item EX-99.1: Item EX-99.1
- November 2026 presentation highlights rinvatercept’s expanding pipeline role across DMD and ALS, increasing potential value beyond a single indication
- Phase 2 DMD basket trial commenced, with initial data expected in first half of 2027
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results and recent business highlights announced for the quarter ended September 30, 2026
- Exhibit 99.1 contains the detailed results and operational updates relevant to investors
Item EX-99.1: Item EX-99.1
- Q3 2026 net income $14.2M, or $0.71 basic EPS, versus $7.3M loss, driven by $40.0M license revenue
- Nine-month net loss $38.3M despite $40.0M license revenue, highlighting continued operating losses without partnering income
AI summaries of KROS 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for KROS
Don't miss the next KROS filing
- Alerts as it files. A push when KROS files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut KROS, by share count.
- Ask anything. An AI agent that reads every KROS filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Newton Charles W. | Sell | Nov 17, 2026 | 491 | $10.83 |
| Newton Charles W. | Sell | Nov 17, 2026 | 60 | $11.05 |
| Prener Anne | Sell | Nov 17, 2026 | 142 | $11.03 |
| Prener Anne | Sell | Nov 17, 2026 | 433 | $10.77 |
| Prener Anne | Sell | Nov 12, 2026 | 574 | $9.79 |
| Cho Esther | Sell | Aug 18, 2026 | 4,485 | $10.29 |
| Lerner Lorena Raquel | Sell | Aug 18, 2026 | 3,568 | $10.29 |
| Tanini Annita | Sell | Aug 18, 2026 | 1,224 | $10.29 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $151K | $3.5M | $244.1M |
| Operating Income | - | -$210.8M | $67.6M |
| Net Income | -$153.0M | -$187.4M | $87.0M |
| Op. Margin | - | -5939.0% | 27.7% |
| Net Margin | -101319.2% | -5277.5% | 35.7% |
| Balance Sheet | |||
| Total Assets | - | $615.9M | $338.0M |
| Equity | - | $571.6M | $303.1M |
| ROE | - | -32.8% | 28.7% |
| Per Share | |||
| EPS | $-5.20 | $-5.00 | $2.30 |
| Cash Flow | |||
| Operating CF | - | -$160.9M | $107.5M |
| CapEx | $2.5M | $1.9M | $1.6M |
Source: XBRL data in Keros Therapeutics, Inc. (KROS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate KROS share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 24 | $103.7M |
| Q2 2026 | 26 | $93.7M |
| Q1 2026 | 27 | $92.4M |
| Q4 2025 | 24 | $190.2M |
| Q3 2025 | 25 | $190.5M |
| Q2 2025 | 26 | $153.5M |
| Q1 2025 | 21 | $124.3M |
| Q4 2024 | 16 | $191.8M |
- BlackRock+707.2K (+25%)
- Two Sigma Investments+301.5K (+122%)
- Goldman Sachs Group+76.3K (+43%)
- Morgan Stanley+56.1K (+71%)
- Bank of America Corp+32.6K (+104%)
- Citadel Advisors LLC−233.4K (-59%)
- AQR Capital Management−163.9K (-17%)
- Millennium Management−108.1K (-58%)
- D.E. Shaw & Co−84.3K (-32%)
- Dimensional Fund Advisors−56.9K (-12%)
- Principal Financial Group−63.8K
- FMR LLC (Fidelity)−35.3K
Source: 13F-HR filings on SEC EDGAR (aggregated from 189 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
KROS filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 19, 2026 | - | - | - |
| 4 | Nov 19, 2026 | - | - | - |
| 4 | Nov 16, 2026 | - | - | - |
| 8-K | Nov 16, 2026 | - | Analysis | - |
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 10-Q | Nov 5, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Sep 29, 2026 | - | Analysis | - |
| 8-K | Sep 28, 2026 | - | Analysis | - |
| 8-K | Sep 8, 2026 | - | Analysis | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 19, 2026 | - | - | - |
| 8-K | Aug 3, 2026 | - | Analysis | - |
| 10-Q | Aug 3, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 3, 2026 | - | Analysis | - |
| 8-K | Jul 30, 2026 | - | Analysis | - |
| 8-K | Jul 22, 2026 | - | Analysis | - |
| 4 | Jul 17, 2026 | - | - | - |
| SC 13G | Jul 17, 2026 | - | - | |
| 4 | Jul 6, 2026 | - | - | - |
| 8-K | Jun 25, 2026 | - | Analysis | - |
| 4 | Jun 17, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
KROS SEC filings: frequently asked questions
Are KROS insiders buying or selling?
In the last 90 days, Keros Therapeutics, Inc. (KROS) officers, directors and 10% owners reported no open-market purchases and 5 open-market sales worth $17,830 by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold KROS stock?
As of September 30, 2026, the largest Keros Therapeutics, Inc. (KROS) holders among the 13F filers tracked by SignalX were BlackRock ($39.9 million), Vanguard Capital Management LLC ($9.5 million), AQR Capital Management ($9.2 million), Vanguard Portfolio Management LLC ($7.3 million), Two Sigma Investments ($6.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was KROS's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Keros Therapeutics, Inc. (KROS) reported revenue of $244.1 million (up 6775.0% from FY2024) and net income of $87.0 million. Diluted EPS was $2.30. The figures come from the XBRL data in the 10-K.
What did KROS report in its latest 8-K?
Keros Therapeutics, Inc. (KROS) filed an 8-K on November 16, 2026 reporting Item 8.01 (Other Events). $5 million common-stock repurchase program approved after receiving a $20 million Takeda development milestone.
What are the latest KROS SEC filings?
Keros Therapeutics, Inc. (KROS) filed its latest 10-K annual report on March 4, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 16, 2026 and a Form 4 insider filing on November 19, 2026.
What is KROS's SEC CIK number?
Keros Therapeutics, Inc. (KROS)'s SEC Central Index Key (CIK) is 1664710. EDGAR lists every KROS filing under that number.
Ask anything about KROS
The research agent reads KROS's filings, financials, insider trades and 13F holders, then answers with sources.